UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates

Drug metabolism and pharmacokinetics, 2009-01, Vol.24 (1), p.53-75

2009

Volltextzugriff (PDF)

Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling

Journal of clinical pharmacology, 2020-07, Vol.60 (7), p.915-930

2020

Volltextzugriff (PDF)

Physiologically based pharmacokinetic modeling of tadalafil to inform pediatric dose selection in children with pulmonary arterial hypertension

CPT: pharmacometrics and systems pharmacology, 2022-02, Vol.11 (2), p.173-184

2022

Volltextzugriff (PDF)

Quantitative Prediction of CYP3A4‐ and CYP3A5‐Mediated Drug Interactions

Clinical pharmacology and therapeutics, 2020-01, Vol.107 (1), p.246-256

2020

Volltextzugriff (PDF)

Physiologically‐Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid‐to‐Lactone Conversion

CPT: pharmacometrics and systems pharmacology, 2019-09, Vol.8 (9), p.664-675

2019

Volltextzugriff (PDF)

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective

Clinical pharmacology and therapeutics, 2018-07, Vol.104 (1), p.88-110

2018

Volltextzugriff (PDF)

Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050

The Journal of pharmacology and experimental therapeutics, 2016-02, Vol.356 (2), p.260

2016

Volltextzugriff (PDF)

Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease

Journal of clinical pharmacology, 2017-06, Vol.57 (6), p.739-746

2017

Volltextzugriff (PDF)

Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects

Journal of clinical pharmacology, 2014-09, Vol.54 (9), p.968-978

2014

Volltextzugriff (PDF)

The use of mechanistic DM‐PK‐PD modelling to assess the power of pharmacogenetic studies –CYP2C9 and warfarin as an example

British journal of clinical pharmacology, 2007-07, Vol.64 (1), p.14-26

2007

Volltextzugriff (PDF)

Incorporating In Vitro Information on Drug Metabolism Into Clinical Trial Simulations to Assess the Effect of CYP2D6 Polymorphism on Pharmacokinetics and Pharmacodynamics: Dextromethorphan as a Model Application

Journal of clinical pharmacology, 2007-02, Vol.47 (2), p.175-186

2007

Volltextzugriff (PDF)

Corrections to “A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of 'Bottom-Up' vs 'Top-Down' Recognition of Covariates”

Drug metabolism and pharmacokinetics, 2009, Vol.24 (5), p.488-488

2009

Volltextzugriff (PDF)

Physiologically Based Pharmacokinetic Model Verification and Improvement for CYP2D6‐mediated Drug‐drug Interaction Prediction

The FASEB journal, 2017-04, Vol.31 (S1)

2017

Volltextzugriff (PDF)

Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease: Journal of Clinical Pharmacology

Journal of clinical pharmacology, 2017-06, Vol.57 (6), p.739-746

2017

Volltextzugriff (PDF)

A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins

CPT: pharmacometrics and systems pharmacology, 2019-11, Vol.8 (11), p.773-776

2019

Volltextzugriff (PDF)

Physiologically based pharmacokinetic modeling to understand the observed drug-drug interaction of LY2623091 with CYP3A inhibitors itraconazole and diltiazem

International journal of pharmacokinetics, 2017-11, Vol.2 (4), p.233-245

2017

Volltextzugriff (PDF)

A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics:A Tale of‘Bottom-Up’vs‘Top-Down’Recognition of Covariates

DRUG METABOLISM AND PHARMACOKINETICS, 2009, Vol.24 (1), p.53-75

2009

Volltextzugriff (PDF)

The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies

British journal of clinical pharmacology, 2007-07, Vol.64 (1), p.14-26

2007

Volltextzugriff (PDF)

Building Virtual Human Populations: Assessing the Propagation of Genetic Variability in Drug Metabolism to Pharmacokinetics and Pharmacodynamics

Biosimulation in Drug Development, 2007, p.425-446

2007

Volltextzugriff (PDF)

Crossing Boundaries in Public Policy and Management: Tackling the Critical Challenges

1st, 2019

Volltextzugriff (PDF)

New models for human disease from the International Mouse Phenotyping Consortium

Mammalian genome, 2019-06, Vol.30 (5-6), p.143-150

2019

Volltextzugriff (PDF)

Evaluating a systematic voiding programme for patients with urinary incontinence after stroke in secondary care using soft systems analysis and Normalisation Process Theory: Findings from the ICONS case study phase

International journal of nursing studies, 2014-10, Vol.51 (10), p.1308-1320

2014

Volltextzugriff (PDF)

Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics

Cancer management and research, 2011-05, Vol.3 (default), p.157-175

2011

Volltextzugriff (PDF)

The Rise of Boundaries

Crossing Boundaries in Public Policy and Management, 2019, p.15-22

1, 2019

Volltextzugriff (PDF)

Where Next for Boundaries?

Crossing Boundaries in Public Policy and Management, 2019, p.53-62

1, 2019

Volltextzugriff (PDF)

1 – 25 von 35

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(21)
Mit Volltextzugriff
(28)

Publikationsform

Sprache

Englisch
(34)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates

Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling

Physiologically based pharmacokinetic modeling of tadalafil to inform pediatric dose selection in children with pulmonary arterial hypertension

Quantitative Prediction of CYP3A4‐ and CYP3A5‐Mediated Drug Interactions

Physiologically‐Based Pharmacokinetic Modeling of Atorvastatin Incorporating Delayed Gastric Emptying and Acid‐to‐Lactone Conversion

Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective

Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050

Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease

Safety, tolerability, and pharmacokinetic evaluation of single- and multiple-ascending doses of a novel kappa opioid receptor antagonist LY2456302 and drug interaction with ethanol in healthy subjects

The use of mechanistic DM‐PK‐PD modelling to assess the power of pharmacogenetic studies –CYP2C9 and warfarin as an example

Incorporating In Vitro Information on Drug Metabolism Into Clinical Trial Simulations to Assess the Effect of CYP2D6 Polymorphism on Pharmacokinetics and Pharmacodynamics: Dextromethorphan as a Model Application

Corrections to “A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of 'Bottom-Up' vs 'Top-Down' Recognition of Covariates”

Physiologically Based Pharmacokinetic Model Verification and Improvement for CYP2D6‐mediated Drug‐drug Interaction Prediction

Population Pharmacokinetics of LY2623091 in Patients With Hypertension and Chronic Kidney Disease: Journal of Clinical Pharmacology

A Quantitative Systems Pharmacology Consortium Approach to Managing Immunogenicity of Therapeutic Proteins

Physiologically based pharmacokinetic modeling to understand the observed drug-drug interaction of LY2623091 with CYP3A inhibitors itraconazole and diltiazem

A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics:A Tale of‘Bottom-Up’vs‘Top-Down’Recognition of Covariates

The use of mechanistic DM-PK-PD modelling to assess the power of pharmacogenetic studies

Building Virtual Human Populations: Assessing the Propagation of Genetic Variability in Drug Metabolism to Pharmacokinetics and Pharmacodynamics

Crossing Boundaries in Public Policy and Management: Tackling the Critical Challenges

New models for human disease from the International Mouse Phenotyping Consortium

Evaluating a systematic voiding programme for patients with urinary incontinence after stroke in secondary care using soft systems analysis and Normalisation Process Theory: Findings from the ICONS case study phase

Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics

The Rise of Boundaries

Where Next for Boundaries?

Suchergebnisse filtern